Sino Biopharmaceutical - SBMFF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.54
+0 (0.00%)

This chart shows the closing price for SBMFF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sino Biopharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBMFF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBMFF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.54.

This chart shows the closing price for SBMFF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Sino Biopharmaceutical. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/2/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy
11/3/2020Daiwa Capital MarketsInitiated CoverageBuy
8/20/2020MacquarieDowngradeOutperform ➝ Neutral
5/12/2020Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
3/19/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/20/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sino Biopharmaceutical logo
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Read More

Today's Range

Now: $0.54
Low: $0.54
High: $0.54

50 Day Range

MA: $0.56
Low: $0.51
High: $0.60

52 Week Range

Now: $0.54
Low: $0.46
High: $0.89

Volume

N/A

Average Volume

226 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Sino Biopharmaceutical?

The following Wall Street analysts have issued research reports on Sino Biopharmaceutical in the last twelve months: Deutsche Bank Aktiengesellschaft.
View the latest analyst ratings for SBMFF.

What is the current price target for Sino Biopharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Sino Biopharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sino Biopharmaceutical in the next year.
View the latest price targets for SBMFF.

What is the current consensus analyst rating for Sino Biopharmaceutical?

Sino Biopharmaceutical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBMFF will outperform the market and that investors should add to their positions of Sino Biopharmaceutical.
View the latest ratings for SBMFF.

What other companies compete with Sino Biopharmaceutical?

Other companies that are similar to Sino Biopharmaceutical include Clinigen Group, MDxHealth, Nicox, Oxford Biomedica and Pharma Mar. Learn More about companies similar to Sino Biopharmaceutical.

How do I contact Sino Biopharmaceutical's investor relations team?

Sino Biopharmaceutical's physical mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company's listed phone number is 852-2802-9886 and its investor relations email address is [email protected] The official website for Sino Biopharmaceutical is www.sinobiopharm.com. Learn More about contacing Sino Biopharmaceutical investor relations.